Cite
HARVARD Citation
McNamara, J. et al. (2019). Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet. 7 (4), pp. 325-335. [Online].